Clinical Trial

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

Study acronym: VESPER-2
Completed Phase 2
View on ClinicalTrials.gov →
Summary
This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.
Protocol Amendment History 2 changes
critical Trial completed 2026-04-18
notable Trial sites expanded: 20 -> 29 locations 2026-04-18
Trial Details
NCT Number NCT06897202
Lead Sponsor Pfizer
Conditions Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
Enrollment 133 participants
Start Date 2025-03-14
Primary Completion 2025-12-29 (estimated)
Study Completion 2026-03-18 (estimated)
Updated on ClinicalTrials.gov 2026-06-12